IL1B and metabolic dysfunction-associated steatotic liver disease: In this study, our results revealed that WEA administration induced a significant decrease in hepatic TNF-α, IL-1β, and IL-6 levels, and the hepatic expression of TNF-α, IL-1β, and IL-6 genes was downregulated in WEA-treated rats with NAFLD, suggesting that the anti-inflammatory activity of WEA might be attributable to the inhibition of the hepatic expression of inflammation-related genes in this animal model.